477OBevacizumab (Bev) or cetuximab (Cet) plus chemotherapy...

Annals of Oncology 2017 / 09 Vol. 28; Iss. suppl_5

477OBevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)

Bennouna, J., Hiret, S., Borg, C., Bertaut, A., Bouche, O., Deplanque, G., Francois, E., Conroy, T., Ghiringhelli, F., des Guetz, G., Seitz, J-F., Artru, P., Stanbury, T., Charpentier, S., Denis, M.,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx393.004
Date:
September, 2017
File:
PDF, 64 KB
english, 2017
Conversion to is in progress
Conversion to is failed